Safety Alerts & Recalls
The FDA is warning pet owners, veterinarians, healthcare providers, and pharmacists that pets are at risk of illness and death when exposed to topical pain medications containing flurbiprofen.
The FDA is alerting healthcare providers and the public that counterfeit Botox (onabotulinumtoxin A; Allergan) has been found in the United States and may have been distributed to doctors' offices and clinics.
The FDA continues to warn consumers and caregivers not to use Eu Yan Sang (Hong Kong) Ltd.'s "Bo Ying compound" because of the possible lead poisoning risk associated with the product.
Baxter International Inc. is voluntarily recalling select lots of intravenous (IV) solutions to the hospital/user level due to the potential presence of particulate matter.
The Food and Drug Administration (FDA) has announced that new, validated manual reprocessing instructions have been issued by Olympus for the TJF-Q180V endoscopic retrograde cholangiopancreatography (ERCP) endoscopes (duodenoscopes) after reports of multi-drug resistant bacterial infections in patients in patients who have undergone ERCP with reprocessed duodenoscopes, even when the manufacturer reprocessing instructions are correctly followed.
The Food and Drug Administration (FDA) is recommending that manufacturers stop using the labels "latex-free" or "does not contain latex" due to the scientific inaccuracy of these claims.
The ASHP and ISMP have issued a National Alert for Serious Medications Errors regarding potentially dangerous mix-ups of neostigmine injection and phenylephrine injection.
The FDA stated the study results were inconclusive regarding the investigation of two deaths following the injection of Zyprexa Relprevv (olanzapine pamoate; Eli Lilly) from June 2013.
The FDA has issued a new safety warning regarding cases of serious and life-threatening symptomatic bradycardia as well as one case of fatal cardiac arrest following the co-administration of amiodarone with either Harvoni (ledipasvir and sofosbuvir fixed-dose combination; Gilead Sciences) or with Sovaldi (sofosbuvir; Gilead Sciences) in combination with another direct-acting antiviral (DAA).
Micro Labs announced a voluntary recall of 54,096 bottles of Simvastatin Tablets due to failed impurities/degradation specifications.
- Certain Food Combos Prevent Weight Gain, While Others Promote It
- The Vitamin D Debate: Conundrums and Complexities
- Maple Syrup Boosts Antibiotic Effects in Proof-of-Concept Research
- New AHA/ACA/ASH Hypertension Guidelines: Lead Author Discusses Treatments and Controversies
- Is an Ancient Potion the Next Antibiotic for MRSA?
- Is Mindfulness Therapy Comparable to Antidepressants to Prevent Depressive Relapse?
- High-Dose Oral Insulin Promising for Preventing T1DM in At-Risk Children
- The Consequences of Ignoring the Complete Medication List
- Strategies Suggested for Helping Children Swallow Meds
- Statins Tenuously Cost-Effective for Primary Prevention in Seniors